who should not take glp-1 receptor agonists Nutritional Deficiencies with weekly (Ozempic & Mounjaro): What patients Need to GLP-1 Receptor Agonists in Solid

Abstract Purpose of Review

Preliminary data from a phase 1b extension study (NCT05292911) involving 64 individuals with MRI-PDFF 10% and BMI 28 kg/m 2 demonstrated that 50%, 44%, and 60% of participants presenting baseline alanine aminotransferase (ALT) 30 IU/L reached combined MRI-PDFF reduction 30% and ALT reduction 17 IU/L at pemvidutide doses of 1.2, 1.8, and 2.4 mg, respectively, vs

GLP-1 agonists also stimulate pancreatic beta cells to secrete insulin and tamp down glucagon secretion from the pancreatic alpha cells

In cases where metformin is not suitable or not sufficient to achieve target blood glucose levels, healthcare providers may consider adding or switching to other medications, such as GLP-1s, DPP-4 inhibitors, SGLT-2 inhibitors, or insulin

Mild to moderate side effects are often observed in the early weeks (~first 6) of medication use and during dose escalation